---
title: "Relutrigine in SCN2A- and SCN8A-related developmental and epileptic encephalopathies: Product information and disease description"
description: "Formulary evidence on Relutrigine in SCN2A- and SCN8A-related developmental and epileptic encephalopathies: Product information and disease description. Covers Product description and Place of product in therapy. 88 evidence topics quoted from 59 sources."
canonical: "https://www.evicenter.com/drugs/relutrigine--scn2a-and-scn8a-related-developmental-and-epileptic-encephalopathies/product-information-and-disease-description"
published: "2026-09-14T15:39:06-04:00"
modified: "2026-11-17T19:46:25-05:00"
---

# Relutrigine in SCN2A- and SCN8A-related developmental and epileptic encephalopathies: Product information and disease description

<a id="product-information-and-disease-description"></a>

## 2 Product Information and Disease Description

<a id="heading-2.1"></a>

### 2.1 Product Description

<a id="heading-2.1.1"></a>

#### 2.1.1 Phase of Product Development

<a id="topic-2.1.1-1"></a>

##### Investigational status

> “Relutrigine remains investigational and is not currently approved by the FDA.”

Source: [The Cute Syndrome Foundation](https://www.thecutesyndrome.com/clinicaltrials.html)

<a id="topic-2.1.1-2"></a>

##### Regulatory status: Under review; NDA submitted in the first quarter of 2026 and accepted March 2026

> “BOSTON, Nov. 09, 2026”
> “The NDA for relutrigine for the treatment of SCN2A and SCN8A DEEs remains under FDA review, with a Prescription Drug User Fee Act (PDUFA) target action date of December 27, 2026.”

Source: [Praxis Precision Medicines third quarter 2026 results announcement (2026)](https://www.globenewswire.com/news-release/2026/11/09/3398230/0/en/praxis-precision-medicines-provides-corporate-update-and-reports-third-quarter-2026-financial-results.html)

> “BOSTON, March 30, 2026”
> “today announced that the U.S. Food and Drug Administration (FDA) has accepted for priority review its New Drug Application (NDA) for relutrigine”

Source: [Praxis Precision Medicines NDA acceptance announcement (2026)](https://www.globenewswire.com/news-release/2026/03/30/3264996/0/en/Praxis-Precision-Medicines-Announces-FDA-Acceptance-and-Priority-Review-of-New-Drug-Application-for-Relutrigine-in-Patients-with-SCN2A-and-SCN8A-DEEs.html)

> “BOSTON, February 19, 2026”
> “we started 2026 with two NDA submissions for ulixacaltamide and relutrigine”
> “Praxis has submitted an NDA for relutrigine for the treatment of SCN2A and SCN8A DEEs”

Source: [Praxis Precision Medicines fourth quarter and full-year 2025 results announcement (2026)](https://www.sec.gov/Archives/edgar/data/1689548/000168954826000028/praxisye2025pr.htm)

<a id="topic-2.1.1-3"></a>

##### FDA acceptance announcement

> “has accepted for priority review its New Drug Application (NDA) for relutrigine”

Source: [Praxis Precision Medicines NDA acceptance announcement (2026)](https://www.globenewswire.com/news-release/2026/03/30/3264996/0/en/Praxis-Precision-Medicines-Announces-FDA-Acceptance-and-Priority-Review-of-New-Drug-Application-for-Relutrigine-in-Patients-with-SCN2A-and-SCN8A-DEEs.html)

<a id="topic-2.1.1-4"></a>

##### Updated regulatory timeline

> “FDA sets updated PDUFA date of December 27, 2026”

Source: [Praxis Precision Medicines extension period announcement (2026)](https://www.globenewswire.com/news-release/2026/06/29/3319308/0/en/praxis-precision-medicines-announces-extension-period-for-relutrigine-for-treatment-of-scn2a-and-scn8a-developmental-and-epileptic-encephalopathies.html)

<a id="topic-2.1.1-5"></a>

##### Additional clinical studies

> “No new clinical studies were requested”

Source: [Praxis Precision Medicines extension period announcement (2026)](https://www.globenewswire.com/news-release/2026/06/29/3319308/0/en/praxis-precision-medicines-announces-extension-period-for-relutrigine-for-treatment-of-scn2a-and-scn8a-developmental-and-epileptic-encephalopathies.html)

<a id="topic-2.1.1-6"></a>

##### Review extension: additional analyses

> “submission of additional sensitivity analyses of existing clinical data”

Source: [Praxis Precision Medicines extension period announcement (2026)](https://www.globenewswire.com/news-release/2026/06/29/3319308/0/en/praxis-precision-medicines-announces-extension-period-for-relutrigine-for-treatment-of-scn2a-and-scn8a-developmental-and-epileptic-encephalopathies.html)

<a id="topic-2.1.1-7"></a>

##### Advisory committee

> “The agency confirmed that no advisory committee meeting is planned.”

Source: [Praxis Precision Medicines second quarter 2026 results announcement (2026)](https://www.globenewswire.com/news-release/2026/08/06/3340217/0/en/praxis-precision-medicines-provides-corporate-update-and-reports-second-quarter-2026-financial-results.html)

<a id="topic-2.1.1-8"></a>

##### Breakthrough Therapy designation announcement

> “Food and Drug Administration (FDA) has granted BTD for relutrigine”

Source: [Praxis Precision Medicines Breakthrough Therapy designation announcement (2025)](https://praxismedicines.gcs-web.com/news-releases/news-release-details/praxis-precision-medicines-receives-fda-breakthrough-therapy)

<a id="topic-2.1.1-9"></a>

##### Other FDA designations

> “Relutrigine has received Orphan Drug Designation (ODD) and Rare Pediatric Disease Designation from the FDA”

Source: [Praxis Precision Medicines NDA filing plans announcement (2025)](https://ir.praxismedicines.com/news-releases/news-release-details/praxis-precision-medicines-announces-plans-file-nda-relutrigine)

<a id="topic-2.1.1-10"></a>

##### FDA orphan designation: SCN8A

| Information                | Quoted record                                                  |
| -------------------------- | -------------------------------------------------------------- |
| Date designated            | “04/08/2021”                                                   |
| Orphan designation         | “Treatment of SCN8A Developmental and Epileptic Encephalopathy” |
| FDA orphan approval status | “Not FDA Approved for Orphan Indication”                       |

Source: [FDA Orphan Drug Designations and Approvals (2021)](https://www.accessdata.fda.gov/scripts/opdlisting/oopd/detailedIndex.cfm?cfgridkey=789620)

<a id="topic-2.1.1-11"></a>

##### European designations

> “EMA: Orphan Drug Designations for SCN2A DEE and SCN8A DEE”

Source: [Praxis Precision Medicines presentation (2026)](https://investors.praxismedicines.com/static-files/c2910f99-1668-45ca-8170-2471c172f2af)

<a id="topic-2.1.1-12"></a>

##### Launch

No evidence found.

<a id="heading-2.1.2"></a>

#### 2.1.2 Product Information

<a id="heading-2.1.2.1"></a>

##### 2.1.2.1 Generic, Brand Name and Therapeutic Class of Product

<a id="topic-2.1.2.1-1"></a>

###### Manufacturer: Praxis Precision Medicines

| Field | Quoted record |
| --- | --- |
| Sponsor | “Praxis Precision Medicines, Inc.” |

Source: [FDA Orphan Drug Designations and Approvals (2021)](https://www.accessdata.fda.gov/scripts/opdlisting/oopd/detailedIndex.cfm?cfgridkey=789620)

<a id="topic-2.1.2.1-2"></a>

###### Product names

> “Relutrigine (PRAX-562)”

Source: [Praxis Precision Medicines EMBOLD results announcement (2025)](https://ir.praxismedicines.com/news-releases/news-release-details/praxis-precision-medicines-announces-positive-results-embold)

<a id="topic-2.1.2.1-3"></a>

###### Drug class

> “a sodium channel functional state modulator for pediatric use”

Source: [Praxis Precision Medicines Breakthrough Therapy designation announcement (2025)](https://praxismedicines.gcs-web.com/news-releases/news-release-details/praxis-precision-medicines-receives-fda-breakthrough-therapy)

<a id="heading-2.1.2.2"></a>

##### 2.1.2.2 Dosage Forms and Strengths

<a id="topic-2.1.2.2-1"></a>

###### Formulation and administration: manufacturer presentation

> “Liquid formulation - oral or G/J tube administration”

Source: [Praxis Precision Medicines presentation (2026)](https://investors.praxismedicines.com/static-files/c2910f99-1668-45ca-8170-2471c172f2af)

<a id="topic-2.1.2.2-2"></a>

###### Clinical product formulation: material safety data sheet

No evidence found.

<a id="topic-2.1.2.2-3"></a>

###### Formulation strength

No evidence found.

<a id="heading-2.1.2.3"></a>

##### 2.1.2.3 Average Sales Price and Wholesale Acquisition Cost

<a id="topic-2.1.2.3-1"></a>

###### Product price and anticipated annual cost per patient

Not applicable.

<a id="heading-2.1.2.4"></a>

##### 2.1.2.4 American Hospital Formulary Service (AHFS), or Other Drug Classification

<a id="topic-2.1.2.4-1"></a>

###### Mechanistic classification

> “a preferential inhibitor of persistent sodium current”

Source: [Praxis Precision Medicines NDA filing plans announcement (2025)](https://ir.praxismedicines.com/news-releases/news-release-details/praxis-precision-medicines-announces-plans-file-nda-relutrigine)

<a id="topic-2.1.2.4-2"></a>

###### AHFS classification

No evidence found.

<a id="heading-2.1.2.5"></a>

##### 2.1.2.5 Indication

<a id="topic-2.1.2.5-1"></a>

###### Indication under regulatory review

> “Praxis has submitted an NDA for relutrigine for the treatment of SCN2A and SCN8A DEEs”

Source: [Praxis Precision Medicines fourth quarter and full-year 2025 results announcement (2026)](https://www.sec.gov/Archives/edgar/data/1689548/000168954826000028/praxisye2025pr.htm)

<a id="heading-2.1.2.6"></a>

##### 2.1.2.6 Pharmacology

<a id="heading-2.1.2.6.1"></a>

###### 2.1.2.6.1 Mechanism of Action

<a id="topic-2.1.2.6.1-1"></a>

###### Proposed mechanism of action

> “a preferential inhibitor of persistent sodium current”

Source: [Praxis Precision Medicines NDA filing plans announcement (2025)](https://ir.praxismedicines.com/news-releases/news-release-details/praxis-precision-medicines-announces-plans-file-nda-relutrigine)

<a id="heading-2.1.2.6.2"></a>

###### 2.1.2.6.2 Pharmacodynamics

<a id="topic-2.1.2.6.2-1"></a>

###### Preclinical pharmacology

> “PRAX-562 also exhibited potent use-dependent block (31× preference to tonic block).”
> “PRAX-562 (10 mg/kg po) completely prevented evoked seizures without affecting sLMA”

Source: [Kahlig et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9304232/)

Additional sources: [Neurology (2023)](https://www.neurology.org/doi/10.1212/WNL.0000000000202328)

<a id="heading-2.1.2.6.3"></a>

###### 2.1.2.6.3 Pharmacokinetics

<a id="topic-2.1.2.6.3-1"></a>

###### Pharmacokinetics and food effect: PRAX-562-101 healthy-volunteer study

> “time to observed maximum concentration (tmax) between 2 and 3 hours.”
> “PRAX-562 can be administered without regard to food.”

Source: [Pfister et al. (2023b)](https://praxismedicines.com/wp-content/uploads/2023/09/IEC2023_562-101_Final_QRcode.pdf)

<a id="topic-2.1.2.6.3-2"></a>

###### Pharmacokinetics and metabolism: EILAT XVIII progress report

> “Relutrigine has a prolonged half-life (median ~110 h in pediatric patients; 129 h in adults)”
> “Metabolism is mediated predominantly by CYP1A2.”

Source: [Bialer et al. (2026)](https://onlinelibrary.wiley.com/doi/full/10.1002/epi.70346)

<a id="heading-2.1.2.7"></a>

##### 2.1.2.7 Contraindications/Warnings/Precautions/Adverse Effects

<a id="heading-2.1.2.7.1"></a>

###### 2.1.2.7.1 Warnings and Precautions

<a id="topic-2.1.2.7.1-1"></a>

###### FDA-approved prescribing information, contraindications, boxed warnings, and REMS

Not applicable.

<a id="heading-2.1.2.8"></a>

##### 2.1.2.8 Special Populations

<a id="topic-2.1.2.8-1"></a>

###### Pediatric trial population: EMBOLD cohort 1

> “2-18 years inclusive; weight ≥10 kg”

Source: [Frizzo et al. (2025)](https://praxismedicines.com/p157_gil-nagel_iec2025_embold-topline/)

<a id="topic-2.1.2.8-2"></a>

###### Healthy-adult pharmacokinetic population

> “healthy adults aged 18-55 years”

Source: [Pfister et al. (2023b)](https://praxismedicines.com/wp-content/uploads/2023/09/IEC2023_562-101_Final_QRcode.pdf)

<a id="topic-2.1.2.8-3"></a>

###### Renal impairment, hepatic impairment, pregnancy, and lactation

No evidence found.

<a id="heading-2.1.2.9"></a>

##### 2.1.2.9 Drug/Drug, Drug/disease Interactions

<a id="heading-2.1.2.9.1"></a>

###### 2.1.2.9.1 Effects of Other Drugs on Relutrigine

<a id="topic-2.1.2.9.1-1"></a>

###### Ciprofloxacin coadministration: increased relutrigine exposure

> “relutrigine exposure (AUC ~31%)”

Source: [Bialer et al. (2026)](https://onlinelibrary.wiley.com/doi/full/10.1002/epi.70346)

<a id="heading-2.1.2.9.2"></a>

###### 2.1.2.9.2 Effects of Relutrigine on Other Drugs

<a id="topic-2.1.2.9.2-1"></a>

###### Relutrigine 120 mg once daily: enzyme inhibition

> “moderate inhibition of CYP1A2 and CYP2D6”

Source: [Bialer et al. (2026)](https://onlinelibrary.wiley.com/doi/full/10.1002/epi.70346)

<a id="heading-2.1.2.10"></a>

##### 2.1.2.10 Dosing and Administration

<a id="heading-2.1.2.10.1"></a>

###### 2.1.2.10.1 Dosage

<a id="topic-2.1.2.10.1-1"></a>

###### Dosing: EMBOLD protocol

> “0.5 mg/kg/day PRAX-562 QD”
> “Dose adjustment is permitted to a maximum of 1.0 mg/kg/day and a minimum of 0.25 mg/kg/day.”

Source: [Pfister et al. (2023c)](https://praxismedicines.com/wp-content/uploads/2023/12/Pfister_AES2023_EMBOLD_Poster_Final.pdf)

<a id="topic-2.1.2.10.1-2"></a>

###### Dosing: manufacturer presentation

> “No titration required”
> “Once daily dosing”

Source: [Praxis Precision Medicines presentation (2026)](https://investors.praxismedicines.com/static-files/c2910f99-1668-45ca-8170-2471c172f2af)

<a id="heading-2.1.2.10.2"></a>

###### 2.1.2.10.2 Administration

<a id="topic-2.1.2.10.2-1"></a>

###### Administration routes: manufacturer presentation

> “Liquid formulation - oral or G/J tube administration”

Source: [Praxis Precision Medicines presentation (2026)](https://investors.praxismedicines.com/static-files/c2910f99-1668-45ca-8170-2471c172f2af)

<a id="topic-2.1.2.10.2-2"></a>

###### Administration with food: healthy-volunteer study

> “PRAX-562 can be administered without regard to food.”

Source: [Pfister et al. (2023b)](https://praxismedicines.com/wp-content/uploads/2023/09/IEC2023_562-101_Final_QRcode.pdf)

<a id="heading-2.1.2.11"></a>

##### 2.1.2.11 Access and Distribution

<a id="topic-2.1.2.11-1"></a>

###### Expanded access

> “Requests will be considered on a case-by-case basis.”
> “All requests must be submitted by the patient’s treating physician.”

Source: [Praxis Precision Medicines](https://praxismedicines.com/eap/)

<a id="topic-2.1.2.11-2"></a>

###### Anticipated patient support

> “establishing a comprehensive patient support program”

Source: [Praxis Precision Medicines second quarter 2026 results announcement (2026)](https://www.globenewswire.com/news-release/2026/08/06/3340217/0/en/praxis-precision-medicines-provides-corporate-update-and-reports-second-quarter-2026-financial-results.html)

<a id="heading-2.1.2.12"></a>

##### 2.1.2.12 Co-prescribed/Concomitant Therapies

<a id="topic-2.1.2.12-1"></a>

###### EMBOLD cohort 2: baseline medication use among relutrigine-exposed participants

| Baseline ASMs | Participants |
| --- | --- |
| 1 to 2 | “17 (33%)” |
| 3 to 6 | “34 (67%)” |

Source: [Kamireddy et al. (2026a)](https://praxismedicines.com/aan2026-10-010/)

<a id="heading-2.1.2.13"></a>

##### 2.1.2.13 Effect of Relutrigine on Quality Measures

No evidence found.

<a id="heading-2.1.2.14"></a>

##### 2.1.2.14 Product comparison

<a id="topic-2.1.2.14-1"></a>

###### Preclinical comparison: protective index in mouse seizure and locomotor assays

| Compound | Protective index |
| --- | --- |
| PRAX-562 | “16.2” |
| Lamotrigine | “4.7” |
| Carbamazepine | “5.9” |

Source: [Kahlig et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9304232/)

<a id="topic-2.1.2.14-2"></a>

###### Direct clinical comparison with another active antiseizure medication

No evidence found.

<a id="heading-2.2"></a>

### 2.2 Place of Product in Therapy

<a id="heading-2.2.1"></a>

#### 2.2.1 Disease Description

<a id="heading-2.2.1.1"></a>

##### 2.2.1.1 Definition and Etiology

<a id="topic-2.2.1.1-1"></a>

###### SCN2A-associated epilepsy: inheritance

> “more than 80% of patients had de novo SCN2A variants.”

Source: [Zeng et al. (2022)](https://www.frontiersin.org/journals/molecular-neuroscience/articles/10.3389/fnmol.2022.809951/full)

<a id="topic-2.2.1.1-2"></a>

###### SCN8A-related epilepsy with encephalopathy: definition

> “SCN8A-related epilepsy with encephalopathy is a condition characterized by recurrent seizures (epilepsy), abnormal brain function (encephalopathy), and intellectual disability.”

Source: [MedlinePlus](https://medlineplus.gov/genetics/condition/scn8a-related-epilepsy-with-encephalopathy/)

<a id="heading-2.2.1.2"></a>

##### 2.2.1.2 Epidemiology

<a id="heading-2.2.1.2.1"></a>

###### 2.2.1.2.1 Incidence of SCN2A- and SCN8A-related developmental and epileptic encephalopathies

<a id="topic-2.2.1.2.1-1"></a>

###### SCN8A-related disorders: Danish birth-cohort frequency

> “We found the frequency of SCN8A related disorders in the Danish population to be 1/56,247”

Source: [Johannesen et al. (2021)](https://air.unimi.it/bitstream/2434/949883/2/SCN8A.pdf)

<a id="topic-2.2.1.2.1-2"></a>

###### SCN2A-related epilepsy: estimated Danish incidence, broader than DEE

> “1 per 78,608 live births”

Source: [Abbott et al. (2024)](https://www.cambridge.org/core/elements/scn2arelated-disorders/ED2438A209BCDABCFC941E8C88803109)

<a id="heading-2.2.1.2.2"></a>

###### 2.2.1.2.2 Prevalence of SCN2A- and SCN8A-related developmental and epileptic encephalopathies

<a id="topic-2.2.1.2.2-1"></a>

###### Epidemiology: combined SCN2A and SCN8A population, manufacturer estimate

> “Estimated prevalence of ~5,000 patients in the US”

Source: [Praxis Precision Medicines EMBOLD topline results presentation (2024)](https://investors.praxismedicines.com/static-files/91013dac-4234-4f1e-8128-88e376d27b3b)

<a id="topic-2.2.1.2.2-2"></a>

###### Epidemiology: SCN8A-related epilepsy and neurodevelopmental disorders

> “The prevalence of SCN8A-related epilepsy and/or neurodevelopmental disorders is not known.”

Source: [GeneReviews](https://www.ncbi.nlm.nih.gov/books/NBK379665/)

Additional sources: [Andrews et al. (2023)](https://pubmed.ncbi.nlm.nih.gov/37577282/)

<a id="heading-2.2.1.3"></a>

##### 2.2.1.3 Natural History, Survival, and Mortality

<a id="topic-2.2.1.3-1"></a>

###### SCN2A-associated epilepsy: onset

> “Nearly 80% of patients started seizures within 6 months of age.”

Source: [Zeng et al. (2022)](https://www.frontiersin.org/journals/molecular-neuroscience/articles/10.3389/fnmol.2022.809951/full)

<a id="topic-2.2.1.3-2"></a>

###### Natural history of SCN8A-related disorders

> “we harmonized electronic medical record data from 82 individuals with SCN8A-related disorders”

Source: [Magielski et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11998016/)

<a id="topic-2.2.1.3-3"></a>

###### Early mortality in SCN8A-related epilepsies

> “In total, we reviewed the data of 190 patients.”
> “the overall mortality was 5.3%.”

Source: [Johannesen et al. (2018)](https://pubmed.ncbi.nlm.nih.gov/29677576/)

<a id="heading-2.2.1.4"></a>

##### 2.2.1.4 Pathophysiology

<a id="topic-2.2.1.4-1"></a>

###### Clinical phenotype spectrum and variant function in SCN2A-related disorders

> “gain-of-function and mixed function variants predominated in neonatal-onset epilepsy”

Source: [Berg et al. (2024)](https://academic.oup.com/brain/article/147/8/2761/7656659)

<a id="topic-2.2.1.4-2"></a>

###### Mechanisms of SCN2A loss of function

> “For personalized treatment, predicting the underlying LoF mechanism should not rely solely on phenotypic grouping.”

Source: [Tan et al. (2026)](https://onlinelibrary.wiley.com/doi/full/10.1002/epi.70100)

<a id="heading-2.2.1.5"></a>

##### 2.2.1.5 Diagnosis

<a id="topic-2.2.1.5-1"></a>

###### Diagnostic genetic testing of the epilepsies

> “We emphasize the importance of genetic testing for individuals with epilepsy”

Source: [Krey et al. (2022)](https://portal.findresearcher.sdu.dk/en/publications/current-practice-in-diagnostic-genetic-testing-of-the-epilepsies/)

<a id="topic-2.2.1.5-2"></a>

###### SCN8A molecular diagnosis

> “a heterozygous pathogenic (or likely pathogenic) variant in SCN8A”

Source: [GeneReviews](https://www.ncbi.nlm.nih.gov/books/NBK379665/)

Additional sources: [ClinicalTrials.gov NCT05818553](https://clinicaltrials.gov/study/NCT05818553)

<a id="heading-2.2.1.6"></a>

##### 2.2.1.6 Clinical Presentation - Signs and Symptoms

<a id="topic-2.2.1.6-1"></a>

###### Neurological symptoms: seizures, encephalopathy, and intellectual disability

> “SCN8A-related epilepsy with encephalopathy is a condition characterized by recurrent seizures (epilepsy), abnormal brain function (encephalopathy), and intellectual disability.”

Source: [MedlinePlus](https://medlineplus.gov/genetics/condition/scn8a-related-epilepsy-with-encephalopathy/)

Additional sources: [Zeng et al. (2022)](https://www.frontiersin.org/journals/molecular-neuroscience/articles/10.3389/fnmol.2022.809951/full)

<a id="heading-2.2.1.7"></a>

##### 2.2.1.7 Long-term Morbidity

<a id="topic-2.2.1.7-1"></a>

###### Development and adaptive function in SCN2A-related disorders

> “Developmental delay/intellectual disability was present in 91 of 100”

Source: [Goad et al. (2025)](https://portal.findresearcher.sdu.dk/en/publications/development-and-adaptive-function-in-individuals-with-scn2a-relat/)

<a id="topic-2.2.1.7-2"></a>

###### Seizure control across SCN8A phenotypes: consensus publication

> “Seizure freedom is rare in patients with Severe DEE but may occur in some with Mild/Moderate DEE and NDDwGE.”

Source: [Conecker et al. (2024a)](https://onlinelibrary.wiley.com/doi/10.1111/epi.17991)

<a id="heading-2.2.1.8"></a>

##### 2.2.1.8 Burden of SCN2A- and SCN8A-related developmental and epileptic encephalopathies

<a id="heading-2.2.1.8.1"></a>

###### 2.2.1.8.1 Humanistic Burden and Health-related Quality of Life

<a id="topic-2.2.1.8.1-1"></a>

###### Literature review: impact of developmental and epileptic encephalopathies on caregivers

> “Sixty-seven relevant studies were identified”

Source: [Gallop et al. (2021)](https://www.sciencedirect.com/science/article/pii/S1525505021005850)

<a id="topic-2.2.1.8.1-2"></a>

###### German burden-of-illness study: quality-of-life outcomes

> “Quality-of-life (KIDSCREEN, HADS, BSFC, EQ-5D)”

Source: [DRKS DRKS00032614](https://drks.de/search/en/trial/DRKS00032614)

<a id="topic-2.2.1.8.1-3"></a>

###### SCN2A-related disorders: trial-readiness for non-seizure outcomes

> “Raw scores increased so slowly over time that standardized scores declined.”

Source: [Berg et al. (2021)](https://pubmed.ncbi.nlm.nih.gov/33236786/)

<a id="topic-2.2.1.8.1-4"></a>

###### SCN2A-related disorders: level of adaptive functioning and change over time

> “Mean standardized VABS scores (Composite 53.5; Motor, 55.8, Communication, 54.1, Socialization, 59.4, and Daily living skills, 55.1) reflected performance ~3 standard deviations below the normative test average.”
> “In longitudinal regression analyses, standardized scores decreased between 1.3 and 2.8 points per year, suggesting regression of abilities.”
> “Participants with epilepsy scored 0.6 to 1 SD lower than those without epilepsy (all P’s < .05).”

Source: [Berg et al. (2021)](https://pubmed.ncbi.nlm.nih.gov/33236786/)

<a id="topic-2.2.1.8.1-5"></a>

###### SCN2A-related disorders: implications for choosing trial endpoints

> “The VABS, as standardly administered, has shortcomings for addressing growth or regression in individuals with SCN2A-DEEs.”
> “Alternative measures sensitive to incremental meaningful change are required if outcomes such as adaptive behavior are to be primary outcomes in short-term clinical trials.”

Source: [Berg et al. (2021)](https://pubmed.ncbi.nlm.nih.gov/33236786/)

<a id="topic-2.2.1.8.1-6"></a>

###### SCN2A-related disorders: gross motor function

> “No motor score changed significantly over time in the longitudinal analyses.”

Source: [Berg et al. (2025b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12054743/)

<a id="topic-2.2.1.8.1-7"></a>

###### SCN2A-related disorders: Vineland-3 growth scale values

> “Floor effects were relatively infrequent on the GSV metric”

Source: [Kaat et al. (2025)](https://pubmed.ncbi.nlm.nih.gov/39887012/)

<a id="topic-2.2.1.8.1-8"></a>

###### SCN2A-related disorders: goal attainment scaling pilot study

> “All 10 caregivers completed the goal-setting interviews”

Source: [Sevinc et al. (2025)](https://inchstoneproject.org/wp-content/uploads/2025/11/The-Feasibility-of-Personalized-Endpoints-in-Asses.pdf)

<a id="topic-2.2.1.8.1-9"></a>

###### Severe neurodevelopmental impairments: meaningful change

> “Meaningful change thresholds have not been evaluated in the DEE literature.”

Source: [Downs et al. (2024)](https://link.springer.com/article/10.1007/s11136-023-03543-6)

<a id="topic-2.2.1.8.1-10"></a>

###### SCN8A-related disorders: quality of life and adaptive functioning

> “Nineteen patients with SCN8A pathogenic variants were included.”

Source: [Xie et al. (2025)](https://pubmed.ncbi.nlm.nih.gov/40208090/)

<a id="topic-2.2.1.8.1-11"></a>

###### SCN8A-related disorders: quality of life and adaptive function by epilepsy phenotype

> “Four participants were classified as SeLFIE (21.1%), 8 as mild-to-moderate DEE (42.1%), 6 as DEE (31.6%), and 1 as NDDwGE (5.2%).”
> “The SeLFIE group had the highest mean QI-Disability total score (94.2 ± 2.1), followed by mild-to-moderate DEE (80.5 ± 11.6), and then DEE (50.5 ± 14.2); F(2, 15) = 20.13, P < .001”
> “Similarly, the SeLFIE group had the highest mean VABS-3 ABC score (103.5 ± 8.6), followed by mild-to-moderate DEE (71.6 ± 4.5), and then DEE (25.5 ± 3.5); F(2, 15) = 49.12, P < .001”

Source: [Xie et al. (2025)](https://pubmed.ncbi.nlm.nih.gov/40208090/)

<a id="topic-2.2.1.8.1-12"></a>

###### SCN8A-related epilepsy: associations with quality of life and adaptive functioning

> “Greater seizure frequency and number of antiseizure medications were both associated with lower VABS and QI-Disability total scores”

Source: [Xie et al. (2025)](https://pubmed.ncbi.nlm.nih.gov/40208090/)

<a id="topic-2.2.1.8.1-13"></a>

###### Genetic developmental and epileptic encephalopathies: caregiver assessment of quality of life

> “QoL scores were strongly associated with the number of days minimally disrupted by seizures, medication side effects, genetic diagnosis, and community type.”

Source: [Cohen et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10305579/)

<a id="topic-2.2.1.8.1-14"></a>

###### Severe neurodevelopmental disorders: caregiver-reported quality of life

> “Mean total QI-Disability score was 60.2 ± 14.1 out of a total possible score of 100.”

Source: [Ludwig et al. (2026)](https://link.springer.com/article/10.1007/s11136-025-04153-0)

<a id="topic-2.2.1.8.1-15"></a>

###### Genetic developmental and epileptic encephalopathies: non-seizure outcomes and caregiver priorities

> “Parents identified expressive communication as a top (N = 211, 79 %) priority for improvement.”

Source: [Berg et al. (2025c)](https://inchstoneproject.org/wp-content/uploads/2025/10/Berg-Priorities-EJPN-2025.pdf)

<a id="topic-2.2.1.8.1-16"></a>

###### Medication-formulation preferences: caregiver survey

> “Across all participants, the most convenient medication formulation was liquid”
> “23 (66%) respondents, regardless of feeding pattern”

Source: [Densmore et al. (2021)](https://praxismedicines.com/wp-content/uploads/2023/09/Densmore_SeizureExhibit_poster_final.pdf)

<a id="topic-2.2.1.8.1-17"></a>

###### SCN8A caregiver priorities: research-roadmap publication

> “caregivers placed higher importance on cognitive impairment, communication difficulties, and behavioral problems”
> “caregivers tended to prioritize immediate, practical interventions to improve daily life”

Source: [SCN8A Research Consortium (2025)](https://link.springer.com/article/10.1186/s13023-025-03672-w)

Additional sources: [Berg et al. (2025a)](https://pubmed.ncbi.nlm.nih.gov/39439575/); [Ludwig et al. (2024)](https://inchstoneproject.org/wp-content/uploads/2025/11/Ludwig-et-al.-2024-Novel-approaches-to-measuring-cognition-in-individ.pdf)

<a id="heading-2.2.1.8.2"></a>

###### 2.2.1.8.2 Economic Burden and Healthcare Resource Utilization

<a id="topic-2.2.1.8.2-1"></a>

###### Existing treatment burden: SCN8A caregiver survey

> “Most patients (77%) were currently taking ≥2 ASMs; 50% had previously tried and stopped ≥4 ASMs.”

Source: [Cutts et al. (2022)](https://pubmed.ncbi.nlm.nih.gov/35325842/)

<a id="topic-2.2.1.8.2-2"></a>

###### SCN2A-related disorders: medical-record study

> “Mean number of medications prescribed by records end across phenotypes was 18.1 (range 0-58)”

Source: [Dalby et al. (2022)](https://praxismedicines.com/wp-content/uploads/2023/09/Dalby_AES2022_SCN2A_Final_Approved_QR.pdf)

<a id="topic-2.2.1.8.2-3"></a>

###### SCN8A-related disorders: medical-record study

> “The mean number of medications prescribed across patients by records end was 17.6 (3-44)”

Source: [Pfister et al. (2022)](https://praxismedicines.com/wp-content/uploads/2023/09/Pfister_AES2022-SCN8A_Final_Approved_QR.pdf)

<a id="topic-2.2.1.8.2-4"></a>

###### German burden-of-illness study: registry recruitment status

> “Recruiting planned”

Source: [DRKS DRKS00032614](https://drks.de/search/en/trial/DRKS00032614)

<a id="topic-2.2.1.8.2-5"></a>

###### German burden-of-illness study: economic outcomes

> “Burden-of-illness (direct and indirect costs - inquired over 3 month period, based on Riechmann et al. Epilepsia 2015)”

Source: [DRKS DRKS00032614](https://drks.de/search/en/trial/DRKS00032614)

<a id="heading-2.2.1.8.3"></a>

###### 2.2.1.8.3 Economic Impact of SCN2A- and SCN8A-related developmental and epileptic encephalopathies on Families

No evidence found.

<a id="heading-2.2.1.8.4"></a>

###### 2.2.1.8.4 Economic Impact of Diagnostic Testing

<a id="topic-2.2.1.8.4-1"></a>

###### UK neonatal epilepsy: earlier gene-panel testing, not relutrigine-specific

> “In neonates, the cost of investigations could be reduced from £9362 to £2838 by performing gene panel earlier”

Source: [Oates et al. (2018)](https://www.nature.com/articles/s41525-018-0052-9)

<a id="heading-2.2.2"></a>

#### 2.2.2 Approaches to Treatment

<a id="heading-2.2.2.1"></a>

##### 2.2.2.1 Current Treatment Options and Standard of Care

<a id="heading-2.2.2.1.1"></a>

###### 2.2.2.1.1 Sodium Channel Blockers

<a id="topic-2.2.2.1.1-1"></a>

###### SCN8A-related epilepsy and neurodevelopmental disorders: global modified Delphi consensus

> “Sodium channel blockers are optimal first-line treatment for GOF, severe DEE, mild/moderate DEE, and SeL(F)IE;”
> “sodium channel blockers are relatively contraindicated in LOF patients.”

Source: [Conecker et al. (2024b)](https://onlinelibrary.wiley.com/doi/full/10.1111/epi.17992)

<a id="topic-2.2.2.1.1-2"></a>

###### SCN2A gain-of-function phenotype: antiseizure medication regimen

> “Ideally AED regimen will include sodium channel-blocking medications, such as phenytoin, lacosamide, oxcarbazepine, carbamazepine, lamotrigine, and zonisamide.”

Source: [FamilieSCN2A Foundation](https://www.scn2a.org/scn2a-related-disorders/clinical-information/)

<a id="topic-2.2.2.1.1-3"></a>

###### SCN8A-related disorders: cenobamate as add-on treatment

> “Countable motor seizures were meaningfully reduced in 10 of 12 patients (83%).”

Source: [Gjerulfsen et al. (2025)](https://pubmed.ncbi.nlm.nih.gov/39812613/)

<a id="topic-2.2.2.1.1-4"></a>

###### SCN8A cenobamate evidence: study design

> “In this retrospective study, the effect of cenobamate was assessed in patients with SCN8A-DEE.”

Source: [Gjerulfsen et al. (2025)](https://pubmed.ncbi.nlm.nih.gov/39812613/)

<a id="heading-2.2.2.1.2"></a>

###### 2.2.2.1.2 Benzodiazepines

<a id="topic-2.2.2.1.2-1"></a>

###### SCN8A status epilepticus: phenytoin and fosphenytoin after first-line benzodiazepines

> “preferred IV therapies for status epilepticus after failing first line benzodiazepines”

Source: [Conecker et al. (2024b)](https://onlinelibrary.wiley.com/doi/full/10.1111/epi.17992)

<a id="heading-2.2.2.1.3"></a>

###### 2.2.2.1.3 Other Antiseizure Medications

<a id="topic-2.2.2.1.3-1"></a>

###### SCN2A later-onset DEE: differential response compared with early-onset DEE

> “respond better to other drug classes including benzodiazepines, levetiracetam, sodium valproate, and ACTH, compared with early onset DEE”

Source: [Abbott et al. (2024)](https://www.cambridge.org/core/elements/scn2arelated-disorders/ED2438A209BCDABCFC941E8C88803109)

<a id="heading-2.2.2.1.4"></a>

###### 2.2.2.1.4 Corticosteroids and Immunoglobulins

<a id="topic-2.2.2.1.4-1"></a>

###### SCN8A: corticosteroids and immunoglobulins when standard ASMs are ineffective

> “may be effective based on anecdotal data.”

Source: [GeneReviews](https://www.ncbi.nlm.nih.gov/books/NBK379665/)

<a id="heading-2.2.2.1.5"></a>

###### 2.2.2.1.5 Ketogenic Dietary Therapy

<a id="topic-2.2.2.1.5-1"></a>

###### SCN8A: modified Delphi consensus

> “Ketogenic diet is somewhat effective in SCN8A patients”

Source: [Conecker et al. (2024b)](https://onlinelibrary.wiley.com/doi/full/10.1111/epi.17992)

<a id="heading-2.2.2.1.6"></a>

###### 2.2.2.1.6 Vagus Nerve Stimulation

<a id="topic-2.2.2.1.6-1"></a>

###### SCN8A: vagus nerve stimulation when standard ASMs are ineffective

> “based on anecdotal data.”

Source: [GeneReviews](https://www.ncbi.nlm.nih.gov/books/NBK379665/)

<a id="heading-2.2.2.1.7"></a>

###### 2.2.2.1.7 Cannabinoids

<a id="topic-2.2.2.1.7-1"></a>

###### SCN8A: cannabinoids when standard ASMs are ineffective

> “based on anecdotal data.”

Source: [GeneReviews](https://www.ncbi.nlm.nih.gov/books/NBK379665/)

<a id="heading-2.2.2.1.8"></a>

###### 2.2.2.1.8 Developmental and Supportive Therapies

<a id="topic-2.2.2.1.8-1"></a>

###### SCN8A: multidisciplinary treatment and early referral

> “Multidisciplinary care of patients with SCN8A is necessary; resources include early referrals, therapies, and complex care.”

Source: [Conecker et al. (2024a)](https://onlinelibrary.wiley.com/doi/10.1111/epi.17991)

<a id="heading-2.2.2.1.9"></a>

###### 2.2.2.1.9 Limitations of Current Therapies

<a id="topic-2.2.2.1.9-1"></a>

###### Summary

Current treatment is heterogeneous and frequently involves several antiseizure medications. The SCN8A caregiver survey found that 77% were taking at least two ASMs and 50% had tried and stopped at least four. Sodium channel blocker recommendations depend on variant function and phenotype: consensus guidance favors them in SCN8A gain-of-function disease but relatively contraindicates them in loss-of-function disease. In SCN2A epilepsy, later-onset disease was associated with less benefit and occasional seizure worsening. The cenobamate evidence cited here is a 12-participant observational series, not a randomized comparison with relutrigine.

Source: [Cutts et al. (2022)](https://pubmed.ncbi.nlm.nih.gov/35325842/); [Conecker et al. (2024b)](https://onlinelibrary.wiley.com/doi/full/10.1111/epi.17992); [Wolff et al. (2017)](https://pubmed.ncbi.nlm.nih.gov/28379373/); [Gjerulfsen et al. (2025)](https://pubmed.ncbi.nlm.nih.gov/39812613/)

<a id="heading-2.2.2.2"></a>

##### 2.2.2.2 Place in Treatment, Anticipated Use, and Care Setting

<a id="topic-2.2.2.2-1"></a>

###### Summary

The studied use of relutrigine is as an investigational treatment for SCN2A- and SCN8A-related DEEs in participants already receiving antiseizure medications. In EMBOLD cohort 2, 34 participants exposed to relutrigine, representing 67%, were taking three to six ASMs at baseline. The manufacturer describes an oral or G/J-tube liquid formulation. Expanded-access requests require submission by the treating physician and are considered individually. These data describe study use and access arrangements, not an approved treatment position.

Source: [Kamireddy et al. (2026a)](https://praxismedicines.com/aan2026-10-010/); [Praxis Precision Medicines presentation (2026)](https://investors.praxismedicines.com/static-files/c2910f99-1668-45ca-8170-2471c172f2af); [Praxis Precision Medicines](https://praxismedicines.com/eap/); [The Cute Syndrome Foundation](https://www.thecutesyndrome.com/clinicaltrials.html)

Additional sources: [Mesraoua et al. (2026)](https://pubmed.ncbi.nlm.nih.gov/41844481/)

<a id="heading-2.2.2.3"></a>

##### 2.2.2.3 Heterogeneity of Treatment Effect

<a id="topic-2.2.2.3-1"></a>

###### Treatment-response heterogeneity in SCN2A-associated epilepsy

> “In contrast, sodium channel blockers were rarely effective in epilepsies with later onset (≥3 months) and sometimes induced seizure worsening.”

Source: [Wolff et al. (2017)](https://pubmed.ncbi.nlm.nih.gov/28379373/)

<a id="heading-2.2.2.4"></a>

##### 2.2.2.4 Care Management Intervention Strategies

<a id="topic-2.2.2.4-1"></a>

###### SCN2A: coordinated epilepsy care

> “Individuals with epilepsy/DEE may be followed by a Complex Care Team and/or Case Management.”

Source: [FamilieSCN2A Foundation](https://www.scn2a.org/scn2a-related-disorders/clinical-information/)

<a id="heading-2.2.2.5"></a>

##### 2.2.2.5 Other Product Development or Post-marketing Obligations Required by the FDA

Not applicable.

<a id="heading-2.2.2.6"></a>

##### 2.2.2.6 Ongoing Post-approval Monitoring

Not applicable.

<a id="heading-2.2.2.7"></a>

##### 2.2.2.7 Expected Outcomes of Therapy

<a id="topic-2.2.2.7-1"></a>

###### Studied therapeutic outcome: motor seizure reduction

> “Relutrigine demonstrated placebo-adjusted seizure reduction in 16 weeks of 46% (p=0.0354) in the first cohort and 53% (p<0.0002) in the confirmatory, registration cohort”

Source: [Kamireddy et al. (2025a)](https://praxismedicines.com/aes138/)

## Related pages
- [Relutrigine: SCN2A- and SCN8A-related developmental and epileptic encephalopathies](https://www.evicenter.com/drugs/relutrigine--scn2a-and-scn8a-related-developmental-and-epileptic-encephalopathies) · [Markdown](https://www.evicenter.com/drugs/relutrigine--scn2a-and-scn8a-related-developmental-and-epileptic-encephalopathies.md)
- [Relutrigine in SCN2A- and SCN8A-related developmental and epileptic encephalopathies: Terms and abbreviations](https://www.evicenter.com/drugs/relutrigine--scn2a-and-scn8a-related-developmental-and-epileptic-encephalopathies/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/relutrigine--scn2a-and-scn8a-related-developmental-and-epileptic-encephalopathies/terms-and-abbreviations.md)
- [Relutrigine: SCN2A- and SCN8A-related developmental and epileptic encephalopathies](https://www.evicenter.com/drugs/relutrigine--scn2a-and-scn8a-related-developmental-and-epileptic-encephalopathies/executive-summary) · [Markdown](https://www.evicenter.com/drugs/relutrigine--scn2a-and-scn8a-related-developmental-and-epileptic-encephalopathies/executive-summary.md)
- [Relutrigine in SCN2A- and SCN8A-related developmental and epileptic encephalopathies: Clinical evidence](https://www.evicenter.com/drugs/relutrigine--scn2a-and-scn8a-related-developmental-and-epileptic-encephalopathies/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/relutrigine--scn2a-and-scn8a-related-developmental-and-epileptic-encephalopathies/clinical-evidence.md)
- [Relutrigine in SCN2A- and SCN8A-related developmental and epileptic encephalopathies: Economic information and modeling report](https://www.evicenter.com/drugs/relutrigine--scn2a-and-scn8a-related-developmental-and-epileptic-encephalopathies/economics) · [Markdown](https://www.evicenter.com/drugs/relutrigine--scn2a-and-scn8a-related-developmental-and-epileptic-encephalopathies/economics.md)
- [Relutrigine in SCN2A- and SCN8A-related developmental and epileptic encephalopathies: References](https://www.evicenter.com/drugs/relutrigine--scn2a-and-scn8a-related-developmental-and-epileptic-encephalopathies/references) · [Markdown](https://www.evicenter.com/drugs/relutrigine--scn2a-and-scn8a-related-developmental-and-epileptic-encephalopathies/references.md)
- [Relutrigine in SCN2A- and SCN8A-related developmental and epileptic encephalopathies: prevalence by geography](https://www.evicenter.com/drugs/relutrigine--scn2a-and-scn8a-related-developmental-and-epileptic-encephalopathies/prevalence) · [Markdown](https://www.evicenter.com/drugs/relutrigine--scn2a-and-scn8a-related-developmental-and-epileptic-encephalopathies/prevalence.md)
- [Relutrigine in SCN2A- and SCN8A-related developmental and epileptic encephalopathies: cost-effectiveness analyses and utility weights](https://www.evicenter.com/drugs/relutrigine--scn2a-and-scn8a-related-developmental-and-epileptic-encephalopathies/cost-effectiveness-analyses) · [Markdown](https://www.evicenter.com/drugs/relutrigine--scn2a-and-scn8a-related-developmental-and-epileptic-encephalopathies/cost-effectiveness-analyses.md)
